- Home
- EVAX vs CNSP Comparison
EVAX vs CNSP Comparison
Compare EVAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CNSP
- Stock Information
- Founded
- EVAX 2008
- CNSP 2017
- Country
- EVAX Denmark
- CNSP United States
- Employees
- EVAX N/A
- CNSP N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- CNSP Health Care
- Exchange
- EVAX Nasdaq
- CNSP Nasdaq
- Market Cap
- EVAX 17.8M
- CNSP 4.0M
- IPO Year
- EVAX 2021
- CNSP 2019
- Fundamental
- Price
- EVAX $2.94
- CNSP $9.14
- Analyst Decision
- EVAX Strong Buy
- CNSP Strong Buy
- Analyst Count
- EVAX 2
- CNSP 1
- Target Price
- EVAX $10.00
- CNSP $20.00
- AVG Volume (30 Days)
- EVAX 71.6K
- CNSP 96.7K
- Earning Date
- EVAX 10-30-2025
- CNSP 11-14-2025
- Dividend Yield
- EVAX N/A
- CNSP N/A
- EPS Growth
- EVAX N/A
- CNSP N/A
- EPS
- EVAX N/A
- CNSP N/A
- Revenue
- EVAX $3,176,000.00
- CNSP N/A
- Revenue This Year
- EVAX N/A
- CNSP N/A
- Revenue Next Year
- EVAX $425.50
- CNSP N/A
- P/E Ratio
- EVAX N/A
- CNSP N/A
- Revenue Growth
- EVAX 1042.45
- CNSP N/A
- 52 Week Low
- EVAX $1.20
- CNSP $4.93
- 52 Week High
- EVAX $17.20
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- EVAX 52.53
- CNSP 68.48
- Support Level
- EVAX $2.81
- CNSP $5.88
- Resistance Level
- EVAX $3.04
- CNSP $9.26
- Average True Range (ATR)
- EVAX 0.20
- CNSP 0.59
- MACD
- EVAX -0.01
- CNSP 0.42
- Stochastic Oscillator
- EVAX 71.19
- CNSP 96.48
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.